Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifampicin and Globalagliatin Interaction Study
NCT04907019Phase 1Completed
- Sponsor
- Yabao Pharmaceutical Group Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of globalagliatin in type 2 diabetes mellitus (T2DM), sponsored by Yabao Pharmaceutical Group Co., Ltd. Primary endpoints: Peak Plasma Concentration (Cmax), Area Under the Curve from time zero to last measurable concentration (AUC0-t) and 1 more. Started Jul 2021; status: completed.
02
Drugs
globalagliatin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04907019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907019.